Cited 0 times in
Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박준용 | - |
dc.contributor.author | 이재승 | - |
dc.date.accessioned | 2021-05-26T16:51:38Z | - |
dc.date.available | 2021-05-26T16:51:38Z | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1542-3565 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182867 | - |
dc.description.abstract | Background & aims: Third-generation cephalosporins (TGCs) are recommended as first-line antibiotics for treatment of spontaneous bacterial peritonitis (SBP). However, antibiotics against multidrug-resistant organisms (such as carbapenems) might be necessary. We aimed to evaluate whether carbapenems are superior to TGC for treatment of SBP. Methods: We performed a retrospective study of 865 consecutive patients with a first presentation of SBP (275 culture positive; 103 with TGC-resistant bacterial infections) treated at 7 referral centers in Korea, from September 2013 through January 2018. The primary outcome was in-hospital mortality. We made all comparisons using data from patients whose baseline characteristics were balanced by inverse probability of treatment weighting. Results: Of patients who initially received empirical treatment with antibiotics, 95 (11.0%) received carbapenems and 655 (75.7%) received TGCs. Among the entire study cohort, there was no significant difference in in-hospital mortality between the carbapenem (25.8%) and TGC (25.3%) groups (adjusted odds ratio [aOR], 0.97; 95% CI, 0.85-1.11; P = .66). In the subgroup of patients with high chronic liver failure-sequential organ failure assessment (CLIF-SOFA) scores (score of 7 or greater, n = 314), carbapenem treatment was associated with lower in-hospital mortality (23.1%) than in the TGC group (38.8%) (aOR, 0.84; 95% CI, 0.75-0.94; P=.002). In contrast, among patients with lower CLIF-SOFA scores (n = 436), in-hospital mortality did not differ significantly between the carbapenem group (24.7%) and the TGC group (16.0%) (aOR, 1.06; 95% CI, 0.85-1.32; P = .58). Conclusions: For patients with a first presentation of SBP, empirical treatment with carbapenem does not reduce in-hospital mortality compared to treatment with TGCs. However, among critically ill patients (CLIF-SOFA scores ≥7), empirical carbapenem treatment was significantly associated with lower in-hospital mortality than TGCs. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | W.B. Saunders | - |
dc.relation.isPartOf | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Empirical Treatment With Carbapenem vs Third-generation Cephalosporin for Treatment of Spontaneous Bacterial Peritonitis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Sun Woong Kim | - |
dc.contributor.googleauthor | Jun Sik Yoon | - |
dc.contributor.googleauthor | Junyong Park | - |
dc.contributor.googleauthor | Yong Jin Jung | - |
dc.contributor.googleauthor | Jae Seung Lee | - |
dc.contributor.googleauthor | Jisoo Song | - |
dc.contributor.googleauthor | Han Ah Lee | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Minjong Lee | - |
dc.contributor.googleauthor | Jin Myung Park | - |
dc.contributor.googleauthor | Dae Hee Choi | - |
dc.contributor.googleauthor | Moon Young Kim | - |
dc.contributor.googleauthor | Seong Hee Kang | - |
dc.contributor.googleauthor | Jin Mo Yang | - |
dc.contributor.googleauthor | Do Seon Song | - |
dc.contributor.googleauthor | Sung Won Chung | - |
dc.contributor.googleauthor | Minseok Albert Kim | - |
dc.contributor.googleauthor | Hee Joon Jang | - |
dc.contributor.googleauthor | Hyunwoo Oh | - |
dc.contributor.googleauthor | Cheol-Hyung Lee | - |
dc.contributor.googleauthor | Yun Bin Lee | - |
dc.contributor.googleauthor | Eun Ju Cho | - |
dc.contributor.googleauthor | Su Jong Yu | - |
dc.contributor.googleauthor | Yoon Jun Kim | - |
dc.contributor.googleauthor | Jung-Hwan Yoon | - |
dc.contributor.googleauthor | Jeong-Hoon Lee | - |
dc.identifier.doi | 10.1016/j.cgh.2020.06.046 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A05963 | - |
dc.relation.journalcode | J02981 | - |
dc.identifier.eissn | 1542-7714 | - |
dc.identifier.pmid | 32623007 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S1542356520309095 | - |
dc.subject.keyword | Ascites | - |
dc.subject.keyword | Cirrhosis | - |
dc.subject.keyword | Risk of Death | - |
dc.subject.keyword | Therapy | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | 박준용 | - |
dc.contributor.affiliatedAuthor | 이재승 | - |
dc.citation.volume | 19 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 976 | - |
dc.citation.endPage | 98600000 | - |
dc.identifier.bibliographicCitation | CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, Vol.19(5) : 976-98600000, 2021-05 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.